✨ Free AI Report
Synlogic, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Synlogic, Inc.
Company Research

Synlogic, Inc.: Business Overview, Financials & Competitive Analysis

Synlogic, Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). High-risk synthetic biology play with transformative potential but facing severe capital constraints and clinical validation challenges. The company pivoted after discontinuing its pivotal Phase 3 study for Phenylketonuria (PKU) in early 2024, an event that triggered a workforce reduction of more than 90%. The company's market capitalization was reported at.

What is Synlogic, Inc.'s industry? Synlogic, Inc. (synlogictx.com) operates in Biotechnology - Synthetic Biology / Rare Metabolic Diseases. AskCyborg classifies Synlogic, Inc. under Biotechnology - Synthetic Biology / Rare Metabolic Diseases in its company registry.

Synlogic is the leading company advancing therapeutics based on synthetic biology, working at the intersection of biology and engineering to treat disease. The biopharmaceutical company engages in the discovery and de...

3/ 10Challenged

Cyborg Score thesis

High-risk synthetic biology play with transformative potential but facing severe capital constraints and clinical validation...

Read the full analyst-debate transcript →
Industry Biotechnology - Synthetic Biology / Rare Metabolic Diseases
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Synlogic, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Synlogic, Inc.

AskCyborg analysts argue the bull and bear cases for Synlogic, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Synlogic, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Synlogic, Inc. Overview

Pro stress-test →

Synlogic is the leading company advancing therapeutics based on synthetic biology, working at the intersection of biology and engineering to treat disease. The biopharmaceutical company engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. The company represents a pioneering attempt to use genetically engineered living probiotics as novel therapeutic agents.

Strategic Profile

Pro stress-test →

The Company focuses on rare metabolic diseases, with its lead program, labafenogene marselecobac (SYNB1934), currently being studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU). The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Strategic partnerships with major pharma and biotech players provide credibility and resources, though the company experienced significant setbacks with a 90%+ workforce reduction in 2024.

Competitive Landscape

Pro stress-test →

Synlogic is based in Winchester, Massachusetts, positioning it within a major biotech hub. Direct competitors in synthetic biology therapeutics are limited, with Ginkgo Bioworks being a key collaborative partner rather than competitor. The company competes broadly with traditional PKU treatments and other rare metabolic disease therapies from larger pharma. Its micro-cap status and clinical setbacks have eroded competitive positioning.

Industry Context

Synlogic, Inc. operates in Biotechnology - Synthetic Biology / Rare Metabolic Diseases.

Key facts

Founded: 2013 · Headquarters: Winchester, MA · Employees: 1 · Revenue: Minimal (collaboration/grant-dependent) · Market cap: $7.78M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Synlogic, Inc..

  • Pioneer in synthetic biology therapeutics using engineered living probiotics designed to treat disease through novel mechanisms.
  • Major clinical setback in early 2024 with discontinuation of pivotal Phase 3 PKU study, leading to 90%+ workforce reduction.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Micro-cap valuation of approximately $7.78M with minimal trading volume indicates severe liquidity challenges
  • Nov 2025Market cap stabilized near $18-19M after dramatic decline from earlier phases
  • +1 moreTrack every material event for Synlogic, Inc. as it happens. Explore monitoring →
Get alerted when Synlogic, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Traditional PKU therapeuticsEstablished dietary and pharmaceutical treatments for phenylketonuria→Cell/gene therapy platformsCollaborative partner on synthetic biology platform development→Rare metabolic disorder therapiesCompeting treatments for homocystinuria, hyperoxaluria, gout→

Compare Synlogic, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Synlogic, Inc. operates in Biotechnology - Synthetic Biology / Rare Metabolic Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Synthetic Biology / Rare Metabolic Diseases research →
NEW · MCP server

Ask your AI assistant about Synlogic, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Synlogic, Inc. and its top competitor on Cyborg Score”
“What did Synlogic, Inc. do this quarter?”
“Is Synlogic, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Synlogic, Inc. do?+
Synlogic is the leading company advancing therapeutics based on synthetic biology, working at the intersection of biology and engineering to treat disease. The biopharmaceutical company engages in the discovery and de...
What is Synlogic, Inc.'s Cyborg Score?+
Synlogic, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Synlogic, Inc.'s main competitors?+
Named competitors include Traditional PKU therapeutics, Cell/gene therapy platforms, Rare metabolic disorder therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Synlogic, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Synlogic, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Synlogic, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.